MedTrace Logo

Antihelminthic Therapy Combined With Antimony in the Treatment of Cutaneous Leishmaniasis

NCT00469495 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2009-08-26

No results posted yet for this study

Summary

The purpose of this project is to investigate the efficacy of early, empiric anti-helminthic therapy combined with standard pentavalent antimony in the treatment of subjects co-infected with helminths and cutaneous leishmaniasis caused by L. brasiliensis. The study hypothesis is that early intervention with antihelminthic therapy will improve response rates to antimony in subjects with cutaneous leishmaniasis.

Conditions

  • Leishmaniasis, Cutaneous
  • Helminthiasis

Interventions

DRUG

Anti-helminthic

DRUG

meglumine antimony

Sponsors & Collaborators

  • Hospital Universitário Professor Edgard Santos

    lead OTHER

Principal Investigators

  • Edgar M Carvalho, MD · Federal University of Bahia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
13 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2008-09-30
Completion
2008-11-30

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00469495 on ClinicalTrials.gov